SITE005 (FRA) › SITE005-0273

SITE005-0273

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2026-07-28

enrolled

AEs

Serious

Dropout signal

–

Adverse events

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-11 (study day 40); relationship: RELATED

severe assessed

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-08 (study day 37); relationship: not assessed

severe assessed

Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-03-07 (study day 36); relationship: NOT RELATED

severe assessed

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-01 (study day 30); relationship: not assessed; serious criteria: hospitalization

severe serious under_review

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-02-20 (study day 21); relationship: RELATED

moderate assessed

Data queries

No data queries. Open queries would appear here for this patient.